Fixed-income securities information
EUR fixed-income securities
| Issuer | Amount (in millions) |
Coupon | Maturity |
|---|---|---|---|
| Novartis Finance S.A. | 1,500 | 4.250% | 2016 |
USD fixed-income securities
| Issuer | Amount (in millions) |
Coupon | Maturity |
|---|---|---|---|
| Novartis Capital Corp. | 2,000 | 4.125% | 2014 |
| Novartis Securities Investment Ltd. |
3,000 | 5.125% | 2019 |
CHF fixed-income securities
| Issuer | Amount (in millions) |
Coupon | Maturity |
|---|---|---|---|
| Novartis Securities Investment Ltd. | 700 | 3.500% | 2012 |
| Novartis AG | 800 | 3.625% | 2015 |
Credit ratings of Novartis AG
| Moody’s | Standard & Poor’s | Fitch | |
|---|---|---|---|
| Short term | P-1 | A-1+ | F1+ |
| Long term | Aa2 | AA- | AA |
| Outlook | Stable | Stable | Stable |
Novartis Finance S.A.
| Principal amount | EUR 1,500,000,000 |
|---|---|
| ISIN | XS0432810116 |
| Issuer | Novartis Finance S.A., Luxembourg |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 4.250% |
| Coupon payment date | June 15 |
| Documentation | EMTN Programme |
| First settlement date | June 15, 2009 |
| Issue price | 99.757 |
| Maturity date | June 15, 2016 |
| Joint book-runners | Barclays Bank, BNP Paribas, Deutsche Bank |
| Bloomberg | NOVART41/4 |
| Listing | London Stock Exchange |
Novartis Capital Corp.
| Principal amount | USD 2,000,000,000 |
|---|---|
| ISIN | US66989HAA68 |
| Issuer | Novartis Capital Corp., United States |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 4.125% |
| Coupon payment dates | February 10, August 10 |
| Documentation | SEC registered shelf registration |
| First settlement date | February 10, 2009 |
| Issue price | 99.897 |
| Maturity date | February 10, 2014 |
| Joint book-runners | JP Morgan, Bank of America, Citi, Goldman Sachs |
| Bloomberg | NOVART41/8 |
Novartis Securities Investment Ltd.
| Principal amount | USD 3,000,000,000 |
|---|---|
| ISIN | US66989GAA85 |
| Issuer | Novartis Securities Investment Ltd., Bermuda |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 5.125% |
| Coupon payment dates | February 10, August 10 |
| Documentation | SEC registered shelf registration |
| First settlement date | February 10, 2009 |
| Issue price | 99.822 |
| Maturity date | February 10, 2019 |
| Joint book-runners | JP Morgan, Bank of America, Citi, Goldman Sachs |
| Bloomberg | NOVART51/8 |
Novartis Securities Investment Ltd.
| Principal amount | CHF 700,000,000 |
|---|---|
| ISIN | CH0043088183 |
| Issuer | Novartis Securities Investment Ltd., Bermuda |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 3.500% |
| Coupon payment date | June 26 |
| Documentation | Swiss stand-alone documentation |
| First settlement date | June 26, 2008 |
| Issue price | 100.32 |
| Maturity date | June 26, 2012 |
| Joint book-runners | Credit Suisse, UBS |
| Bloomberg | NOVART3½ |
| Listing | SIX Swiss Exchange |
Novartis AG
| Principal amount | CHF 800,000,000 |
|---|---|
| ISIN | CH0043089009 |
| Issuer | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 3.625% |
| Coupon payment date | June 26 |
| Documentation | Swiss stand-alone documentation |
| First settlement date | June 26, 2008 |
| Issue price | 100.3500 |
| Maturity date | June 26, 2015 |
| Joint book-runners | Credit Suisse, UBS |
| Bloomberg | NOVART35/8 |
| Listing | SIX Swiss Exchange |
The information provided on this website does not constitute investment advice, or an offer of, or an invitation by, or on behalf of, Novartis AG or any of its subsidiaries, to subscribe for, purchase or sell any securities, including any of the securities described above and below. The information provided also does not constitute an offer, and may not be used for the purpose of an offer to, or a solicitation by, anyone in any jurisdiction or in any circumstances in which such an offer or solicitation is not authorized or is unlawful. You should always seek advice whether governing law permits the use or possession of the information provided.
Neither Novartis AG, nor any of its subsidiaries or employees accepts any liability for any direct or consequential loss arising from any use of the information provided. In particular, neither Novartis AG, nor any of its subsidiaries or employees accepts any liability for any third party content that may be viewed on this site. All information provided is also qualified in its entirety by reference to the relevant prospectuses, supplemental information or other documentation related to the securities described above and below.
Corporate publications
Download our latest financial reports.
Form 20-F
(1.1 MB)
FAQ for investors
Read answers to frequently-asked investor questions.